Radio-isotopes

Tender description

Supply of Radium 223 Dichloride for treating hormone — relapsed prostate cancer with bone metastases (TA376) to the University Hospitals of North Midlands NHS Trust. For a period of 2 years initially with the option to extend 2 x 12 month periods. The Trust is seeking bid proposals in order to establish a 2 year contract with the option to extend 2 x 12 months with a single provider to supply NICE approved Radium 223 Injections. Radium 223 Dichloride supplied as a licensed therapeutic alpha-emitting solution for intravenous injection for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Supplied in a form suitable for the administration of 55 kBq per kg body weight, with the anticipation that the administration will be repeated at an interval of 4 weeks for a total of 6 injections per patient. This product should only be delivered between 9.00 a.m.-5 p.m. Monday-Friday (excluding bank holidays) to the University Hospitals of North Midlands NHS Trust. Due to the nature of radioactive decay each vial is ordered for a set date of injection for a specific body weight. Anticipated usage is sufficient for: Year 1 — 25 patients per year (i.e: up to 150 injections per year); Year 2 – 40 patients year (i.e. up to 240 injections per year); Year 3 — (extension year 1) – 40 patients year (i.e. up to 240 injections per year); Year 4 — (extension year 2) – 40 patients year (i.e. up to 240 injections per year). The successful supplier will have a fully Licensed Radium 223 drug which is approved and funded by NICE. The announcement of a possible future requirement is not to be construed as confirmation that a contract will subsequently be issued. The issue of a possible future requirement, or the issue of an invitation to tender, is not to be construed as a firm commitment by the authority to place an order as a result of the tendering stage or at a later stage. Any expenditure, work or effort prior to any contract award is accordingly a matter solely for the commercial judgment of the tenderer.